Audience: CC All Location: Benefits/A-Z List Updated: 2.2.23

Reviewed: 2.2.23

Cimerli (Ranibizumab-Eqrn)

Drug names

- 1. Cimerli
- 2. Ranibizumab-egrn

Description

Cimerli (ranibizumab-eqrn) is used to prevent vision loss or blindness in certain eye conditions that cause fluid to leak into the macula, including wet age-related macular degeneration resulting from the growth of abnormal blood vessels, and macular edema.

Cimerli is made from a human antibody fragment. It works by inhibiting the biologic activity of human vascular endothelial growth factor A (VEGF-A), a protein that is thought to play an important role in the formation of new blood vessels.

It is administered by intravitreal injection.

See also

Similar, related, or easily confused documents.

- Avastin (Bevacizumab) for Ocular Indications Another VEGF inhibitor.
- Beovu (Brolucizumab-dbll) Age-related macular degeneration treatment.
- Eylea (Aflibercept) Another type of VEGF inhibitor.
- <u>Laser Treatments for Neovascularization Associated with Macular Degeneration</u> Macular degeneration (MD) treatment.
- <u>Lucentis (Ranibizumab)</u> Another type of VEGF inhibitor.
- Macugen (Pegaptanib Sodium) Another type of VEGF inhibitor.
- Photodynamic Therapy with Visudyne (Verteporfin) for Ocular Indications Intravenous (IV) infusion activated by light.
- Susvimo (Ranibizumab) Another VEGF inhibitor.
- <u>Vabysmo (Faricimab-Svoa)</u> Another VEGF inhibitor.

Table of Contents

The following topics are included in this document:

- Commercial
- Government Programs
- Individual and Family Business (IFB)
- MHPS

Document history

Date	Description			
2.2.23	New A-Z sheet.			

Commercial

Introduction

This section applies to all Commercial members.

Benefits

A Pharmacy Clinical Guideline, Cimerli (ranibizumab-eqrn), is on Magellan Rx Management.

- Requires prior authorization through Magellan. Refer to Review Criteria.
- DOS prior to 2.1.23: See New-to-Market Medical Pharmacy Products.
- Important: Check policy for limits or exclusions.
- **ER or inpatient hospital POS**: PA is not required.
- **Providers**: Certain providers are excluded. Refer to <u>Injectable Drug Prior Authorization (Magellan Rx)</u>.
- If approved, covered based on place of service. Quote office visit or outpatient hospital benefits.

Document history

	Date	Description			
	2.2.23	New A-Z sheet.			

Government Programs

Introduction

This section applies to all Medicaid and Medicare products.

AccessAbility (SNBC),

Medicaid only groups:

Refer to <u>Medicaid</u> below.

Minnesota Senior Care Plus (MSC+)

Medicare eligible groups:

- Quote office visit or outpatient hospital benefits.
- Medicare is the primary payer.
- Follows Medicare guidelines.
- If no Medicare eligibility, Medicaid applies. Refer to Medicaid below.

AccessAbility Enhanced (SNBC SNP),

A Pharmacy Clinical Guideline, Cimerli (ranibizumab-eqrn), is on Magellan Rx Management.

DUAL (MSHO)

• Requires prior authorization through Magellan. Refer to Review Criteria.

- DOS prior to 2.1.23: See New-to-Market Medical Pharmacy Products.
- Important: Check policy for limits or exclusions.
- **ER or inpatient POS**: PA is not required.
- Providers: Certain providers are excluded. Refer to Injectable Drug Prior Authorization (Magellan Rx).
- If approved, covered based on place of service. Quote office visit or outpatient hospital benefits.
- Medica is the only payer.

Advantage

A Pharmacy Clinical Guideline, Cimerli (ranibizumab-eqrn), is on Magellan Rx Management.

- Requires prior authorization through Magellan. Refer to Review Criteria.
 - DOS prior to 2.1.23: See <u>New-to-Market Medical Pharmacy Products</u>.
- **Important**: Check policy for limits or exclusions.
- ER or inpatient POS: PA is not required.
- **Providers**: Certain providers are excluded. Refer to <u>Injectable Drug Prior Authorization (Magellan Rx)</u>.
- Professionally administered drugs pull multiple benefits. It is important to quote ALL benefits.
 - **Drug administration**: Quote office visit benefits. Check EOC for cost sharing.
- Injection (J-code): Quote Part B Prescription Drugs in the EOC.
- Medica is the only payer.

Advantage PartnerCare (I-SNP)

A Pharmacy Clinical Guideline, Cimerli (ranibizumab-eqrn), is on Magellan Rx Management.

- Requires prior authorization through Magellan. Refer to Review Criteria.
 - DOS prior to 2.1.23: See New-to-Market Medical Pharmacy Products.
 - Important: Check policy for limits or exclusions.
- − ER or inpatient POS: PA is not required.
- Providers: Certain providers are excluded. Refer to <u>Injectable Drug Prior Authorization (Magellan Rx)</u>.
- Professionally administered drugs pull multiple benefits. It is important to quote ALL benefits.
- **Drug administration**: Quote office visit benefits. Check EOC for cost sharing.
- Injection (J-code): Quote Part B Prescription Drugs in the EOC.
- Medica is the only payer.

Medicaid (SPP)

A Pharmacy Clinical Guideline, Cimerli (ranibizumab-eqrn), is on Magellan Rx Management.

- Requires prior authorization through Magellan. Refer to Review Criteria.
 - DOS prior to 2.1.23: See New-to-Market Medical Pharmacy Products.
 - Important: Check policy for limits or exclusions.
 - ER or inpatient hospital POS: PA is not required.
 - Providers: Certain providers are excluded. Refer to Injectable Drug Prior Authorization (Magellan Rx).
- If approved, covered based on place of service. Quote office visit or outpatient hospital benefits.

Prime

Professionally administered drugs pull multiple benefits. It is important to quote ALL benefits.

- Drug administration: Quote office visit benefits. Check EOC for cost sharing.
- Injection (J-code): Quote Part B Prescription Drugs in the EOC.
- Reminder: Members can use non-Medica Service Area providers. Refer to Out-of-MSA Benefits.

Select,

Quote office visit or outpatient hospital benefits.

Signature

- Medicare supplement. Medicare is the primary payer.
- Follows Medicare guidelines.

Government Programs, Continued

Document history

Date	Description			
2.2.23	New A-Z sheet.			

Individual and Family Business (IFB)

Introduction

This section applies to all Individual and Family Business (IFB) members.

Benefits

A Pharmacy Clinical Guideline, Cimerli (ranibizumab-eqrn), is on Magellan Rx Management.

- Requires prior authorization through Magellan. Refer to Review Criteria.
- DOS prior to 2.1.23: See New-to-Market Medical Pharmacy Products.
- Important: Check policy for limits or exclusions.
- **ER or inpatient hospital POS**: PA is not required.
- Providers: Certain providers are excluded. Refer to <u>Injectable Drug Prior Authorization (Magellan Rx)</u>.
- If approved, covered based on place of service. Quote office visit or outpatient hospital benefits.

Document history

	Date	Description			
	2.2.23	New A-Z sheet.			

Medica Health Plan Solutions (MHPS)

Introduction	This section applies to all Medica Health Plan Solutions (MHPS) members.							
Mayo Medical Plan	Quote office visit or outpatient hospital benefits.							
All others	A Pharmacy Clinical Guideline, Cimerli (ranibizumab-eqrn), is on Magellan Rx Management.							
	• Requires prior authorization through Magellan. Refer to Review Criteria.							
	-	r to 2.1.23: See New-to-Market N						
	- Important: Check policy for limits or exclusions.							
	– ER or inpatient hospital POS : PA is not required.							
	 Providers: Certain providers are excluded. Refer to Injectable Drug Prior Authorization (Magellan Rx). 							
	• If approved, covered based on place of service. Quote office visit or outpatient hospital benefits.							
history	Date 2.2.23	New A-Z sheet.	Description					
Applicability	The applicability is outlined below.							
	Business Segments							
	■ All □ COM - (All) □ GOVT - (All) □ IFB □ MHPS □ PSC							
	Specific Clients/Products							
	■ All □ Other:							
	Platform or System							
	☐ All ■ N/A ☐ Other:							
	Departments							
	■ Call Center □ Multiple: □ Other:							
	Approved By	1	Document Owner	Da	ate			
	A-Z Review	Team	KN Technical Writers	2.2	2.23			